FDA approves therapy for GSDIa - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves therapy for GSDIa

The one-time gene therapy is intended to restore the deficient enzyme needed to release stored glucose during fasting.

  • By

  • Kathryn Wighton

  • August 20, 2026

  • 2 min

Share

Original Source(s)

FDA approves therapy for GSDIa

  • by Kathryn Wighton

  • August 20, 2026

Related Content

The Uncertain Future of Research in Transgender Health

SCPC Care: Non-Age-Related Factors Contribute to Timing

A literature review published in Future Cardiology suggests that providers should look beyond chronological age to various modifiable physiologic factors when planning a superior cavopulmonary connection (SCPC) procedure.

  • by

  • August 12, 2026

  • 6 min
Long-term effects of permanent pacemaker therapy on growth in children with complete heart block